---
title: "The Innovative Drugs ETF (159992) rose 1% during the session, with trading volume ranking first among the same underlying assets. Institutions: By 2026, China's innovative drug BD will undergo three major transformations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279874034.md"
description: "On March 20th, the CSI Innovative Drugs Industry Index rose by 1.08%, the Innovative Drugs ETF (159992) increased by 1%, with a trading volume exceeding 96 million yuan, ranking first among the same underlying assets. Jianghai Securities predicts that by 2026, China's innovative drug business development will undergo three major transformations: technology output joint product licensing, platform cooperation, and global parallel innovation. It is recommended to focus on core tracks such as small nucleic acids, tumor immunity, metabolic diseases, and CGT"
datetime: "2026-03-20T02:04:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279874034.md)
  - [en](https://longbridge.com/en/news/279874034.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279874034.md)
---

# The Innovative Drugs ETF (159992) rose 1% during the session, with trading volume ranking first among the same underlying assets. Institutions: By 2026, China's innovative drug BD will undergo three major transformations

On March 20, the three major indices rose collectively, with the CSI Innovative Drugs Industry Index up 1.08% as of the time of publication. Among the constituent stocks of this index, Zai Lab, Xinlitai, and Jichuan Pharmaceutical rose over 3%, while Kelun Pharmaceutical, Efang Bio, and Watson Bio also followed suit.

In terms of related ETFs, **the Innovative Drugs ETF (159992) rose 1% as of the time of publication, with a trading volume exceeding 96 million yuan, ranking first among the same underlying assets**, and trading was active during the session.

According to Wind Financial Terminal data, as of March 19, **the latest circulating shares of the Innovative Drugs ETF (159992) were 18.356 billion shares, with a latest circulating scale of 14.661 billion yuan.**

The Innovative Drugs ETF (159992) closely tracks the CSI Innovative Drugs Industry Index, which selects no more than 50 of the most representative listed company securities from those involved in innovative drug research and development as index samples, to reflect the overall performance of listed company securities in the innovative drug industry.

**Jianghai Securities** stated that by 2026, China's innovative drug BD will undergo three major transformations: technology output joint product licensing, platform cooperation, and global parallel innovation. It is recommended to focus on core tracks such as small nucleic acids (delivery technology/chronic disease pipelines), tumor immunity (dual antibodies/ADC combination), metabolic diseases (GLP-1 modified varieties/MASH liver-targeted siRNA), and CGT (in vivo gene editing/universal CAR-T).

### Related Stocks

- [159835.CN](https://longbridge.com/en/quote/159835.CN.md)
- [516080.CN](https://longbridge.com/en/quote/516080.CN.md)
- [560900.CN](https://longbridge.com/en/quote/560900.CN.md)
- [159992.CN](https://longbridge.com/en/quote/159992.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [CSPC’s ADC SYS6010 Wins New Breakthrough Status in China Esophageal Cancer](https://longbridge.com/en/news/285925629.md)
- [Universal Digital Inc. Announces Termination of ETF Partnership Agreement | LFGMF Stock News](https://longbridge.com/en/news/286616540.md)
- [Peter Menziuso Named EVP and President, BD Interventional | BDX Stock News](https://longbridge.com/en/news/286757706.md)
- [BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System | BDX Stock News](https://longbridge.com/en/news/287204464.md)